ProCE Banner Activity

Cancer Conversations™: Experts Discuss the New Immunotherapy Paradigm in Endometrial Cancer

Multimedia

Watch this on-demand Webcast of a live CCO Webinar in which a panel of international experts discuss the current evidence for immunotherapy for patients with endometrial cancer.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Released: March 30, 2021

Expiration: March 29, 2022

No longer available for credit.

Share

Faculty

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Azra Raza

Azra Raza, MD

Professor of Medicine
Director,
MDS Center
Columbia University Medical Center
New York, New York

Supporters

Supported by an educational grant from

GlaxoSmithKline

Target Audience

This educational program is intended for ex-US gynecologic oncologists, medical oncologists, nurses and other healthcare providers who care for patients with endometrial cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate current and emerging clinical trial data regarding new immunotherapy treatment options for patients with endometrial cancer
  • Assess MSI and dMMR status as part of recommended molecular subtyping and genomic characterization of endometrial carcinomas at baseline and following recurrence
  • Describe the role of immune checkpoint inhibitor-based therapy in endometrial cancer classified as microsatellite stable

Faculty Disclosure

Primary Author

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Isabelle Ray Coquard, MD, PhD has disclosed that she has received consulting fees from AstraZeneca, Clovis, Genmab, PharmaMar, Roche, and Tesaro and fees for non-CME/CE services from AstraZeneca, Clovis, PharmaMar, and Tesaro.

Azra Raza, MD

Professor of Medicine
Director,
MDS Center
Columbia University Medical Center
New York, New York

Mansoor Raza Mirza, MD, has disclosed that he has received consulting fees from AstraZeneca, GlaxoSmithKline, Merck, and Roche; fees for non-CME/CE services from AstraZeneca, GlaxoSmithKline, and Roche, and funds for research support from Apexigen, AstraZeneca Boehringer Ingelheim, Clovis Oncology, Pfizer, Tesaro-GSK, and Ultimovacs.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.s

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Goal


The goal of this activity is to educate ex-US gynecologic oncologists, medical oncologists, nurses and other healthcare professionals about the recent developments in the use of immunotherapy in the treatment of endometrial cancer and incorporating new data and new therapies into their patient treatment plans.